English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 2 April 2020, 15:30 HKT/SGT
Share:
    

Source: TNB AURA
TNB Aura launches Special Situations Fund, backing tech startups with US$2M each

SINGAPORE, Apr 2, 2020 - (ACN Newswire) - WHO declared COVID-19 a pandemic, its message balancing the inevitability of the virus' global ramifications, with the observation that governments, businesses, and individuals still possess the critical ability to alter the outbreak's trajectory. With businesses abruptly curtailing operations across most sectors, only a select set of companies are well positioned to take advantage of the current situation, while the majority are not.

TNB Aura Co-founders and Managing Partners Vicknesh R Pillay and Charles Wong.


TNB Aura has launched a new Special Situations Fund, backing tech companies impacted by the pandemic with ~US$2M each.

"While we continue investing in growth companies in South East Asia via our first fund, and soon to be second, we see an opportunity to support great companies which are facing near-term cash flows issues as a result of The COVID-19 black swan event," Co-founder and Managing Partner, Vicknesh R Pillay commented. "Our highly selective and hands on approach to investing has proven resilient, reflecting as such in a majority of our portfolio companies. With our financial acumen, we assist our investee companies to be nimble in the manner in which they manage their cash flow, budgeting and talent optimization through volatility."

By providing an extended runway of 12-18 months to weather the headwinds, the fund serves to aid companies in returning their focus to achieving their targeted milestones. "We are investing for the long term, and seek to provide an encouraging narrative to the ecosystem at this critical time. Ultimately, we believe in strong fundamentals, and in the ability of selected companies to both weather the current storm and come out stronger on the other side," said Co-founder and Managing Partner, Charles Wong.

"With the market having previously witnessed a glut of over-valued deals, and today, a current value dislocation, TNB AURA is targeting value deals of high quality for this new fund," Pillay added. TNB AURA aims to turnaround funding within 1-2 months, with the fund open to a range of funding structures such as convertible notes or direct equity. For all interested applicants, please apply through the Special Situations Fund Form. All applications will be dealt with, with the highest confidentiality.

About TNB Aura
TNB Aura is a Singapore headquartered venture capital firm focused on Series A and B technology investments in the region. Founded by entrepreneurs and fund managers who have established, grown and exited several businesses, TNB Aura looks to become the marquee venture capital fund in South East Asia. We believe in people and companies with strong fundamentals, and invest $1mil-$5mil into the next wave of technology-led high growth companies.

For further information, please contact:
Vicknesh R Pillay
Managing Partner, TNB Aura
E: vicknesh@tnbaura.com
M: +65 9009 6164

Charles Wong
Managing Partner, TNB Aura
E: charles.wong@aura.co
M: +65 8250 2525

Topic: Press release summary
Source: TNB AURA

Sectors: Blockchain Technology, PE, VC & Alternatives
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Masverse Unveils Groundbreaking Blockchain Platform  
Apr 27, 2024 02:40 HKT/SGT
Spritzer Scores Big with 'Meet the Red Legends' Event for Football Fans  
Apr 26, 2024 23:00 HKT/SGT
Announcing Mad About Marketing - A New Member of the Digital Sukoon Private Limited Family  
Apr 26, 2024 22:25 HKT/SGT
FinTech Funding Continues to Surge as Second Edition of Dubai FinTech Summit Commences  
Apr 26, 2024 21:10 HKT/SGT
TIME Interconnect Technology Limited Announces Final Results For The Nine Months Ended 31 December 2023  
Apr 26, 2024 18:26 HKT/SGT
UK advertising reports GBP36.6bn spend in 2023  
Apr 26, 2024 17:30 HKT/SGT
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine  
Apr 26, 2024 15:36 HKT/SGT
Edvantage Group Announces FY2024 Interim Results  
Apr 26, 2024 13:43 HKT/SGT
Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Project  
Apr 26, 2024 13:27 HKT/SGT
Imexpharm Corporation Hosts Shareholders, Analysts and Potential Investors at its 2024 Annual General Meeting  
Apr 26, 2024 13:16 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575